Ashvattha Therapeutics
PrivateLast Round
Series B
Extension
Jan 13, 2025
Total Funding Raised
$149.21M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ashvattha Therapeutics is a biotechnology company that develops hydroxyl dendrimer therapeutics to address unmet medical needs in oncology, ophthalmology, and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ashvattha Therapeutics Comparables
Compare Ashvattha Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AsclepiX Therapeutics | 84% | |
| Aviceda Therapeutics | 81% | |
| Oculis Holding | 77% | |
Ashvattha Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 13, 2025 | ||||
| Grant | Sep 1, 2022 | ||||
| Series B | Apr 27, 2022 | ||||
| Series A | Apr 29, 2021 | ||||
| Early Funding | Sep 1, 2020 | ||||
Seed | May 7, 2019 |
Ashvattha Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Natural Capital | Series B, Seed, Series B Extension |
| Plum Alley Investments | Series B |
| Tribe Capital | Series B, Seed, Series B Extension |
| Natural Capital | Series B Extension, Series B |
| National Institute on Aging | Grant |
| Sand Hill Angels | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 46% MoM to 4.6K.
- Jan 9, 2026
George Montgomery appointed as new Executive Chairman.
Ashvattha Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ashvattha Therapeutics's valuation, stock price, and market status.